These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23370238)

  • 21. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug regulation: a sometimes unhealthy coalition.
    Iheanacho I
    BMJ; 2010 May; 340():c2613. PubMed ID: 20484352
    [No Abstract]   [Full Text] [Related]  

  • 23. Medicines Commission.
    Br Med J; 1968 Feb; 1(5589):396-7. PubMed ID: 5635930
    [No Abstract]   [Full Text] [Related]  

  • 24. Product liability.
    Br Med J; 1979 Jun; 1(6179):1663-4. PubMed ID: 466173
    [No Abstract]   [Full Text] [Related]  

  • 25. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

  • 26. A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.
    McGillion FB
    Methods Find Exp Clin Pharmacol; 1979 Apr; 1(1):45-50. PubMed ID: 552581
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug discovery gets an academic push.
    Cancer Discov; 2011 Jul; 1(2):93-4. PubMed ID: 22586346
    [No Abstract]   [Full Text] [Related]  

  • 28. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-commercial drugs.
    Smith AJ
    Proc R Soc Med; 1977 Jan; 70(1):1. PubMed ID: 859824
    [No Abstract]   [Full Text] [Related]  

  • 30. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crying wolf on drug safety.
    Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107
    [No Abstract]   [Full Text] [Related]  

  • 32. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 33. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 34. Open Innovation in Drug Discovery research comes of age.
    Judd DB
    Drug Discov Today; 2013 Apr; 18(7-8):315-7. PubMed ID: 23220636
    [No Abstract]   [Full Text] [Related]  

  • 35. EU must encourage medicines availability and innovation, says NOAH.
    Vet Rec; 2014 Nov; 175(17):415-6. PubMed ID: 25359735
    [No Abstract]   [Full Text] [Related]  

  • 36. An audience with Patrick Vallance.
    Vallance P
    Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993
    [No Abstract]   [Full Text] [Related]  

  • 37. Interview with Graham Warrellow by Isaac Bruce.
    Warrellow G
    Future Med Chem; 2012 Jun; 4(9):1047-51. PubMed ID: 22709249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the LD50 test in the pharmaceutical industry.
    Dayan AD; Clark B; Jackson M; Morgan H; Charlesworth FA
    Lancet; 1984 Mar; 1(8376):555-6. PubMed ID: 6142263
    [No Abstract]   [Full Text] [Related]  

  • 39. The ABPI Data Sheet Compendium 1974.
    Drug Ther Bull; 1974 May; 12(11):43-4. PubMed ID: 4457293
    [No Abstract]   [Full Text] [Related]  

  • 40. Boehringer promoted off-label drug to patients, finds watchdog.
    Kmietowicz Z
    BMJ; 2011 Dec; 343():d8251. PubMed ID: 22188945
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.